Cells that are deficient in homologous recombination, such as those that lack functional breast cancer-associated 1 (BRCA1) or BRCA2, are hypersensitive to inhibition of poly(ADP-ribose) polymerase (PARP). However, BRCA-deficient tumors represent only a small fraction of adult cancers, which might restrict the therapeutic utility of PARP inhibitor monotherapy. Cyclindependent kinase 1 (Cdk1) phosphorylates BRCA1, and this is essential for efficient formation of BRCA1 foci. Here we show that depletion or inhibition of Cdk1 compromises the ability of cells to repair DNA by homologous recombination. Combined inhibition of Cdk1 and PARP in BRCA-wild-type cancer cells resulted in reduced colony formation, delayed growth of human tumor xenografts and tumor regression with prolonged survival in a mouse model of lung adenocarcinoma. Inhibition of Cdk1 did not sensitize nontransformed cells or tissues to inhibition of PARP. Because reduced Cdk1 activity impaired BRCA1 function and consequently, repair by homologous recombination, inhibition of Cdk1 represents a plausible strategy for expanding the utility of PARP inhibitors to BRCA-proficient cancers.
Cdk1 is a core component of the cell cycle machinery, and forms complexes with cyclins A and B to promote S, G2 and M phase progression [1] [2] [3] . Cdk1 and other family members have been shown to participate upstream in DNA damage response pathways [4] [5] [6] [7] [8] . The function of BRCA1 in S phase checkpoint control is compromised in Cdk1-depleted cells; consequently, cancer cells are sensitized to a range of DNA-damaging agents. Cdk1 phosphorylates BRCA1 at Ser1497 and at the double phosphorylation site Ser1189 and Ser1191, and this phosphorylation is necessary for BRCA1 to efficiently form foci at sites of DNA damage and to facilitate checkpoint activation 8 .
BRCA1 is also crucial for DNA repair by homologous recombination 9 . When PARP is inhibited, single-strand breaks (SSBs) degenerate to more lethal double-strand breaks (DSBs) that require repair by homologous recombination. Therefore, BRCA-negative cells and other cells that are deficient in homologous recombination are highly susceptible to PARP inhibition [10] [11] [12] [13] , and this finding has been clinically validated [14] [15] [16] . Here we show that Cdk1 is necessary not only for BRCA1-mediated S phase checkpoint activation, but also for homologous recombination. Consequently, cancer cells in which Cdk1 is depleted or inhibited were defective in homologous recombination and sensitized to PARP inhibition both in vitro and in vivo. Furthermore, nontransformed cells or tissues did not become sensitized to treatment with a PARP inhibitor. Therefore, depletion or inhibition of Cdk1 creates a state of 'BRCAness' 17 in transformed cells and represents a rational approach for expanding the efficacy of PARP inhibitors to BRCA-proficient cancer populations.
RESULTS
Compromised Cdk1 activity reduces homologous recombination BRCA1-deficient cells do not efficiently form Rad51 foci 11, 18 , a crucial component of the homologous recombination repair machinery. We therefore hypothesized that, in addition to checkpoint activation 8 , Cdk1-mediated phosphorylation of BRCA1 would also be required for DNA repair by homologous recombination. We measured the ability of wild-type and S1189A S1191A S1497A triple-mutant BRCA1 8 , as well as an empty vector control, to restore Rad51 foci in response to γ irradiation in the MDA-MB-436 breast cancer cell line, which harbors a deleterious BRCA1 mutation 19 . We could not detect Rad51 foci in parental or empty vector cells under any condition. Compared to cells that expressed wild-type BRCA1, cells that expressed the S1189A S1191A S1497A mutant showed a 64% reduction (P = 0.015) in formation of Rad51 foci in response to γ irradiation (Fig. 1a) . Therefore, Cdk1-mediated phosphorylation of BRCA1 was required for efficient recruitment of both BRCA1 and Rad51 to sites of DNA damage.
To determine whether the formation of Rad51 foci is also reduced in Cdk1-depleted cells, where BRCA1 does not efficiently form foci 8 , we used NCI-H1299 non-small-cell-lung cancer (NSCLC) cells engineered to inducibly express short hairpin RNA (shRNA) targeting Cdk1 or Cdk2 upon doxycycline exposure 20 . Depletion of Cdk1 resulted in an 80% reduction (P = 0.001) in Rad51 focus formation after γ irradiation compared to cells with normal Cdk1 expression ( Fig. 1b) , consistent with compromised homologous recombination repair. By contrast, depletion of Cdk2 did not affect the formation of Rad51 foci (Supplementary Fig. 1 ). The small-molecule Cdk1 inhibitor also reduced the focus-forming capacity of BRCA1 after DNA damage 8 . Compared to parental NCI-H1299 cells pretreated with vehicle, 71% fewer (P = 0.0001) cells pre-treated with RO-3306 efficiently formed Rad51 foci in response to γ irradiation ( Fig. 1c) . Neither Cdk1 depletion nor RO-3306 affected the formation of foci of phosphorylated histone H2AX (γ-H2AX) ( Fig. 1b,c) , a biological marker of the presence of DNA damage.
To directly assess the impact of depletion or inhibition of Cdk1 on homologous recombination, we used a gene conversion assay in which GFP expression indicated the occurrence of homologous recombination 22 . Depletion of Cdk1 using individual or pooled siRNAs resulted in a 44% (P = 0.0035) to 72% (P = 0.0018) reduction in GFP expression compared to control siRNA-treated U2OS pDR-GFP cells (Fig. 1d) . By contrast, siRNA-mediated depletion of Cdk2 did not routinely reduce GFP expression ( Supplementary  Fig. 2) . To account for possible off-target effects of Cdk1 siRNA, we reconstituted U2OS pDR-GFP cells with empty vector or a Cdk1 expression construct containing a silent mutation conferring Cdk1 siRNA resistance. Compared to control siRNA, Cdk1 siRNA resulted in a 32% (P = 0.019) reduction in GFP expression in empty (a) Detection of BRCA1, Rad51 and DAPI by immunofluorescence after γ irradiation in empty vector (V), wildtype (WT) or S1189A S1191A S1497A mutant, HA-tagged BRCA1-expressing MDA-MB-436 cells. Left, representative foci-containing cells; Right, mean ± s.e.m. number of BRCA1-expressing cells with ≥5 Rad51 foci over three experiments. vector -containing cells. However, Cdk1 siRNA did not reduce exogenous silent mutationcontaining Cdk1 protein expression, and subsequently there was no reduction in GFP expression ( Fig. 1e) . The small-molecule Cdk1 inhibitor RO-3306 also reduced GFP expression by 87% (P = 0.013) compared to DMSO-treated control cells. The Cdk inhibitor AG024322 (ref. 23) had similar effects ( Fig. 1f ) and also preferentially inhibited Cdk1 (ref. 20; Supplementary Fig. 3 ).
Depletion of Cdk1 with PARP inhibition results in cell death
The failure to repair DSBs by homologous recombination underlies the sensitivity of BRCA1-deficient cells to PARP inhibitors 11 . We reasoned that Cdk1-depleted cells would be similarly sensitive to PARP inhibition. First, we examined the ability of Cdk1-depleted cells to recruit BRCA1 and Rad51 to sites of DNA damage after treatment with the PARP-1 and PARP-2 inhibitor AG14361 (ref. 24 ). When we treated NCI-H1299 cells expressing normal amounts of Cdk1 with AG14361 for 24 h, it resulted in DNA DSBs that were repaired by homologous recombination, as indicated by the formation of foci of γ-H2AX, BRCA1 and Rad51. However, as for γ irradiation, depletion of Cdk1, but not Cdk2, caused a 76% (P = 0.0013) and 82% (P = 0.0004) reduction in the number of cells with BRCA1 and Rad51 foci, respectively. Formation of γ-H2AX foci was unaffected ( Fig. 2a) . Furthermore, when we treated Cdk1-depleted NCI-H1299 cells with AG14361, the number of chromosome aberrations per cell detected by metaphase spread analyses increased 3.8-fold (P = 0.011) compared with vehicle or 2.7-fold (P = 0.029) compared with AG14361 treatment in cells with normal Cdk1 expression ( Fig. 2b) .
Consequently, after 24 h of AG14361 treatment, Cdk1-depleted cells accumulated at the G2-M boundary, in contrast to cells with normal Cdk1 expression, or cells depleted of Cdk2, which showed little change in cell cycle profile ( Fig. 2c,d) . At later time points after AG14361 treatment, cells with normal Cdk1 expression or depleted of Cdk2 did not undergo cell death. By contrast, Cdk1-depleted cells began to die out of the S and G2-M phases of the cell cycle, as indicated by increased TUNEL positivity 72 h after treatment with AG14361 ( Fig. 2c,d) .
Reduced Cdk1 activity sensitizes to PARP inhibition
We next examined whether Cdk1 depletion could sensitize NSCLC cells to PARP inhibition in long-term colony assays. NCI-H1299 and A549 cells engineered to inducibly express shRNA targeting Cdk1 upon doxycycline exposure (NCI-H1299-Cdk1 and A549-Cdk1 cells) were 220-fold (P = 0.006) and 110-fold (P = 0.0019) more sensitive to AG14361, respectively (representing 99.5% and 99.1% reductions in AG14361 half-maximal lethal concentration (LC 50 ), respectively), in the presence of doxycycline when compared to its absence, whereas Cdk2 depletion did not sensitize these cells (Fig. 3a) . In addition, multiple Cdk1 siRNA constructs sensitized NCI-H1299 cells to treatment with AG014699, a newer generation PARP inhibitor currently in clinical trials 25, 26 , but Cdk2 siRNA constructs did not ( Supplementary Fig. 4 ). Depletion of PARP-1 from NCI-H1299 cells by shRNA caused substantial reduction in colony formation only when Cdk1 was concomitantly depleted (Fig. 3b) . Furthermore, to account for possible off-target effects of Cdk1 shRNA, we engineered NCI-H1299-Cdk1 cells to express an empty vector or an exogenous Cdk1 protein containing a silent mutation that confers resistance to Cdk1-targeting shRNA. In cells containing empty vector, the addition of doxycycline resulted in a 97.8% (P = 0.0066) reduction in the LC 50 of AG014699, compared to cells grown in the absence of doxcycline ( Fig. 3c) . By contrast, the presence of doxycyline did not sensitize cells expressing a Cdk1 protein containing a silent mutation to AG014699 treatment (Fig. 3c) . The effects of Cdk1 knockdown were replicated with small-molecule Cdk1 inhibitors. RO-3306 reduced the LC 50 of AG14361 and AG014699 by 82% (P = 0.001) and 84% (P = 0.0012), respectively (Fig. 3d) . In addition, the degree of Cdk1 inhibition mediated by RO-3306 correlated with the degree of sensitization to PARP-1 inhibition (Supplementary Fig. 5 ). AG024322 also reduced the LC 50 value of AG014699 by 95% (P = 0.0001; Fig. 3e ). We further investigated the mechanism by which Cdk1 depletion sensitized cells to PARP inhibition and assessed the ability of wild-type and S1189A S1191A S1497A triple-mutant BRCA1 to render the MDA-MB-436 cell line 19 resistant to PARP inhibitors. MDA-MB-436 cells containing an empty vector construct were highly sensitive to AG014699 treatment (LC 50 0.006 µM). When cells expressed wild-type BRCA1, the LC 50 value for AG014699 treatment increased 32-fold (P = 0.0018) compared to empty vector cells. By contrast, when cells expressed the triple mutant form of BRCA1, the LC 50 value increased fivefold (P = 0.001) compared to empty vector cells (Fig. 3f) . Furthermore, when MDA-MB-436 cells were treated concomitantly with RO-3306 and AG014699, cells reconstituted with wild-type BRCA1 but not triple-mutant BRCA1 were sensitized to AG014699 treatment (Fig. 3g) . In addition, if reduced Cdk1 activity sensitized cells to PARP inhibition primarily through abrogation of BRCA1 function, then Cdk1 depletion should not further sensitize BRCA1deficient cells. In the absence of doxycycline, BRCA1 depletion sensitized NCI-H1299 cells to AG014699 treatment to a similar degree as doxycycline-induced depletion of Cdk1 (Fig. 3h) . However, there was no further reduction in colony formation after AG014699 treatment in cells that were depleted of BRCA1 and Cdk1 together (Fig. 3h) .
In addition to NCI-H1299 cells, colony formation was lower in A549 and MDA-MB-231 cell lines concomitantly treated with AG014699 and RO-3306 than in those treated with AG014699 alone (Fig. 4a) . In contrast to transformed cells, nontransformed retinal pigment epithelial (RPE) cells were less sensitive to combined RO-3306 and AG014699 treatment (Fig. 4a) or to Cdk1 siRNA and AG014699 treatment than were cancer cell lines (Fig. 4b) . Unlike NCI-H1299 cells, Cdk1 depletion resulted in potent and prolonged G2-M cell cycle arrest in RPE cells. Subsequently, RPE cells were not exposed to S-phase-specific DNA damage mediated by PARP inhibitors, and we detected few TUNEL-positive cells (Fig. 4c) . Treatment with AG014699 resulted in an increase in γ-H2AX in RPE cells treated with control siRNA but not in the G2-M-accumulated, Cdk1-depleted RPE cells (Fig. 4d) . Furthermore, we treated Hs578T breast cancer cells and a nontransformed breast epithelial cell line derived from the same individual, Hs578Bst (ref. 27) , with RO-3306 and AG014699. Only Hs578T cells were sensitized to AG014699 by RO-3306 ( Fig. 4e) . We obtained similar data with the Cdk inhibitor AG024322 (Fig. 4f) .
Compromise of Cdk1 and PARP activities delays tumor growth
To measure the efficacy of combinations of Cdk1 and PARP inhibitors in vivo, we established xenografts of NCI-H1299 cells that inducibly expressed shRNA targeting Cdk1 upon exposure to doxycycline in athymic nu/nu mice. Mice were subsequently fed either normal or doxycycline-containing diets and treated for 23 d with either vehicle or AG014699. Neither doxycycline nor AG014699 alone affected xenograft growth. However, when mice were fed doxycyclinecontaining food and treated with AG014699, tumor growth was substantially delayed (Fig. 5a) . The mean relative tumor volume (RTV) of mice on doxycycline-containing diets and treated with AG014699 was 80% lower (P = 0.0013) than that of mice treated with AG014699 without doxycycline (Fig. 5b) . We confirmed Cdk1 knockdown in xenografts by western blotting (Fig. 5c ). In addition, AG014699 treatment resulted in an increase in γ-H2AX in tumors (Fig. 5c) . RO RO-3306 is rapidly cleared from plasma, so the drug concentrations that are necessary to inhibit Cdk1 cannot be sustained (data not shown). To test the combination of systemic Cdk and PARP inhibition, we used AG024322, which has suitable pharmacokinetic properties for in vivo studies 23 . We treated mice bearing NCI-H1299 xenografts with vehicle or AG024322 followed by vehicle or AG014699 daily for 18 d. Individually, AG024322 and AG014699 had modest effects on tumor growth. However, in mice treated with both compounds, tumor growth was significantly delayed (Fig. 5d) , with a 60% (P = 0.0005), 55% (P = 0.02) and 55% (P = 0.0007) reduction in RTV at day 13 in mice treated with both AG024322 and AG014699 compared to mice treated with vehicle, AG024322 alone or AG014699 alone, respectively (Fig. 5e) . In addition, the combination of AG024322 and AG014699 did not induce significant weight loss over the time course of the treatment (Fig. 5f) .
We next assessed pharmacodynamic markers of the activity of AG024322 and AG014699 in tumor xenografts. AG014699-mediated inhibition of PARP resulted in an increase in the number of cells containing foci of phosphorylated BRCA1 (pSer1189) and total BRCA1 (Fig. 5g) . However, after combined treatment with AG024322 and AG014699, the percentages of cells containing phosphorylated BRCA1 (pSer1189) and total BRCA1 foci were reduced by 71% (P = 0.035) and 49% (P = 0.0029), respectively, compared to AG014699 treatment alone (Fig. 5g) . By contrast, AG024322 did not affect the percentage of cells that contained γ-H2AX foci. Furthermore, only the combination of AG024322 and AG014699 significantly reduced the mitotic count (56% reduction compared to vehicle treated tumors; P = 0.0083) while increasing the apoptotic count (4.96-fold compared to vehicle treated tumors; P = 0.0092), as measured by Aurora B and TUNEL staining, respectively (Fig. 5g) .
Combined Cdk1 and PARP inhibition prolongs survival
We further assessed the therapeutic efficacy of combined inhibition of Cdk1 and PARP in the Kras G12D Trp53 L/L mouse model of lung adenocarcinoma. This model carries an inducible oncogenic Kras G12D allele (Kras LSL-G12D/WT , in which LSL denotes Lox-stop-Lox) as well as a conditional loss-of-tumor suppressor function Trp53 allele (p53 L/L , in which L/L denotes Flox/Flox) 28 . Mice were inoculated with adenoviral Cre (adeno-Cre) by inhalation, transducing a small percentage of pulmonary cells and resulting in cooperation of activated KRas and Trp53 loss to produce highly lethal tumors. We used western blotting to validate BRCA1 expression in these lung tumors (Fig. 6a) . Magnetic resonance imaging (MRI) showed that mice treated 8-9 weeks after adeno-Cre for 1 week with vehicle or AG024322 all had growing tumors. Only two out of eight (25%) mice treated with AG014699 had a small reduction in tumor volume after 1 week of treatment (up to 11% regression). By contrast, 14 out of 16 (87.5%) mice treated for 1 week with both AG024322 and AG014699 showed a reduction in tumor volume (up to 70% regression; Fig. 6a,b) . After 3 weeks of treatment, all mice treated with vehicle, AG024322 or AG014699 alone had substantial tumor growth. However, 9 out of 13 (69%) mice treated with combined AG024322 and AG014699 maintained reduced tumor volume (up to 82% regression; Fig. 6b and Supplementary Fig. 6 ). Tubulin   T1  T1  T1  T2  T2  T2 γ-H2AX By 6 weeks, two of the mice that were treated with combined AG024322 and AG014699 continued to have low tumor volume ( Supplementary  Fig. 6) . Combined AG024322 and AG014699 treatment resulted in a marked reduction in Ki67 staining and increased TUNEL staining in residual tumor compared to vehicle or individual treatments (Fig. 6a) . Kaplan-Meier analyses indicated that the median survival of mice treated with both AG024322 and AG014699 increased by 86% (P = 0.0014), 58% (P = 0.0031) and 70% (P = 0.0027) compared to that of mice treated with vehicle, AG024322 alone or AG014699 alone, respectively (Fig. 6c) . The two mice treated with both AG024322 and AG014699 that had reduced tumor volume at 6 weeks were alive 15 weeks after treatment (Fig. 6c) , and the response to treatment was maintained. Assessment of pathology showed no toxicity or damage to normal mouse tissues and organs after 1, 2 or 4 weeks of combination treatment (Supplementary Figs. 7 and 8) .
DISCUSSION
Depletion or inhibition of Cdk1 in lung cancer cells reduces the formation of BRCA1 foci and the activation of DNA damage-induced checkpoint control 8 . We have now implicated Cdk1 in repair by homologous recombination in these cells. When PARP was inhibited, reduced Cdk1 activity resulted in chromosomal aberrations and cell death, in agreement with previous findings that cells deficient in homologous recombination are hypersensitive to treatment with PARP inhibitors [10] [11] [12] . Furthermore, Cdk1 was previously identified in an siRNA library screen designed to identify proteins whose depletion causes sensitivity to PARP inhibitors 29 . Unlike Cdk1, Cdk2 phosphorylates BRCA2 and impairs its interaction with Rad51, thereby limiting homologous recombination until cell cycle arrest is accomplished and Cdk2 activity extinguished 30 . Consistent with these data, depletion of Cdk2 did not significantly reduce homologous recombination in the cell lines examined, and in several instances, increased the percentage of GFP-positive cells in the gene conversion assay.
In yeast, Cdk1 is essential for multiple steps of homologous recombination 4 . Although Cdk1 might directly influence the function of other homologous recombination proteins, it is likely that reduced Cdk1 activity sensitizes cells to PARP inhibition by disrupting BRCA1 function in lung cancer cells. Depletion of Cdk1 induced an increase in sensitivity to PARP inhibition of more than 100-fold, similar to what is seen in BRCA1-deficient cells 11 , and combined depletion of Cdk1 and BRCA1 did not sensitize cells to a greater degree than depletion of either alone. Selective Cdk1 inhibition does not affect DNA-end resection in these cells, probably because Cdk2 can compensate in this process; such compensation does not occur in the formation of BRCA1 foci 8 .
Our in vitro observations were translated in xenograft models, in which Cdk1 inhibition resulted in a reduction in the PARP inhibitor-mediated increase in cells containing BRCA1 foci but not in cells containing γ-H2AX foci. We also studied mice with lung-specific conditional activating Kras and inactivating Trp53 mutations that develop highly aggressive lung adenocarcinomas with short latency compared to those driven by Kras G12D alone 28, 31 . Kras G12D tumors with concomitant p53 inactivation are also less responsive to cytotoxic therapy than those with wild-type p53 (ref. 32 ). The combination of Cdk and PARP inhibitors induced regression and disease stabilization over 1-3 weeks of treatment in established tumors. Although resistance was documented by 6 weeks, a subset of mice showed a sustained response, so that combination therapy significantly increased median survival. Our results suggest a possible approach to lung cancers harboring this genotype, which frequently have poor outcomes 33 , as well as to other BRCA-proficient tumors.
Mice treated with both AG024322 and AG014699 had no toxicity to organs or normal tissue. In accordance with these observations, depletion or inhibition of Cdk1 did not sensitize RPE cells or nontransformed HS578TBst breast epithelial cells to inhibition of PARP in vitro. Of note, Cdk2 cannot compensate for the loss of Cdk1 in cellular proliferation in nontransformed cells to the same degree as in cancer cells 34 ; consequently, RPE cells were arrested at G2-M when Cdk1 was depleted. After inhibition of PARP, SSBs degenerated to DSBs during traversal of S phase; nontransformed cells, which arrested in G2-M after depletion of Cdk1, probably did not accumulate SSBs followed by DSBs because they did not accumulate γ-H2AX, and are therefore not sensitive to combined inhibition of Cdk1 and PARP. The data therefore suggest that combinations of Cdk and PARP inhibitors will have a therapeutic window.
Our data support the clinical development of combined Cdk1 and PARP inhibition. Analysis of Cdk-mediated phosphorylation of BRCA1 suggests that a 70-90% reduction in Cdk1 activity by small-molecule inhibitors results in sensitization to PARP inhibition in vitro, translating to substantial anti-tumor activity in vivo, and serves as a guide for the degree of inhibition that will be desirable in clinical trials.
In summary, we have used targeted kinase inhibition to inactivate BRCA1, handicap the homologous recombination DNA repair machinery and selectively sensitize transformed cells to PARP inhibition. This approach avoids the use of toxic DNA-damaging chemotherapeutic drugs, thereby providing the potential to extend well-tolerated PARP inhibition to treatment for BRCA-proficient cancers.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
